Table Graph
      published meta-analysis   sensitivity analysis   studies

Spikevax - first boost in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultsAbu-Raddad, 2022 0.53 [0.47; 0.59] Accorsi, 2022 0.31 [0.28; 0.34] Tan, 2022 0.20 [0.14; 0.27] 0.33[0.20; 0.52]Abu-Raddad, 2022, Accorsi, 2022, Tan, 2022397%NAnot evaluable hospitalizationdetailed resultsTan, 2022 0.08 [0.01; 0.56] 0.08[0.01; 0.56]Tan, 202210%NAnot evaluable symptomatic Covid-19detailed resultsAbu-Raddad, 2022 0.53 [0.47; 0.59] Accorsi, 2022 0.31 [0.28; 0.34] 0.40[0.24; 0.69]Abu-Raddad, 2022, Accorsi, 2022298%NAnot evaluable severe COVID-19 occurrencedetailed resultsTan, 2022 0.08 [0.01; 0.56] 0.08[0.01; 0.56]Tan, 202210%NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-14 09:26 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1329 - roots T: 1329

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons